Literature DB >> 16407116

Cyclin-dependent kinase 5 activity regulates pain signaling.

Tej K Pareek1, Jason Keller, Sashi Kesavapany, Harish C Pant, Michael J Iadarola, Roscoe O Brady, Ashok B Kulkarni.   

Abstract

Several molecules and cellular pathways have been implicated in nociceptive signaling, but their precise molecular mechanisms have not been clearly defined. Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase implicated in the development and disease of the mammalian nervous system. The precise role of this kinase in sensory pathways has not been well characterized. Here we report a molecular role for Cdk5 in nociception. We identified the expression of Cdk5 and its activator p35 in nociceptive neurons, which is modulated during a peripheral inflammatory response. Increased calpain activity in sensory neurons after inflammation resulted in the cleavage of p35 to p25, which forms a more stable complex with Cdk5 and, consequently, leads to elevation of Cdk5 activity. p35 knockout mice (p35(-/-)), which exhibit significantly decreased Cdk5 activity, showed delayed responses to painful thermal stimulation compared with WT controls. In contrast, mice overexpressing p35, which exhibit elevated levels of Cdk5 activity, were more sensitive to painful thermal stimuli than were controls. In conclusion, our data demonstrate a role for Cdk5/p35 activity in primary afferent nociceptive signaling, suggesting that Cdk5/p35 may be a target for the development of analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407116      PMCID: PMC1325969          DOI: 10.1073/pnas.0510405103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Induction of c-fos-like protein in spinal cord neurons following sensory stimulation.

Authors:  S P Hunt; A Pini; G Evan
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

2.  Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling.

Authors:  Satoru Takahashi; Toshio Ohshima; Andrew Cho; Taduru Sreenath; Michael J Iadarola; Harish C Pant; Yong Kim; Angus C Nairn; Roscoe O Brady; Paul Greengard; Ashok B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

Review 3.  The molecular dynamics of pain control.

Authors:  S P Hunt; P W Mantyh
Journal:  Nat Rev Neurosci       Date:  2001-02       Impact factor: 34.870

4.  Colocalization of the mu-opioid receptor and calcium/calmodulin-dependent kinase II in distinct pain-processing brain regions.

Authors:  I Brüggemann; S Schulz; D Wiborny; V Höllt
Journal:  Brain Res Mol Brain Res       Date:  2000-12-28

5.  p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment.

Authors:  J Ko; S Humbert; R T Bronson; S Takahashi; A B Kulkarni; E Li; L H Tsai
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

6.  Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB.

Authors:  J Chen; Y Zhang; M B Kelz; C Steffen; E S Ang; L Zeng; E J Nestler
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

7.  The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia.

Authors:  Susanne Kunz; Ellen Niederberger; Corina Ehnert; Ovidiu Coste; Anja Pfenninger; Jochen Kruip; Thomas M Wendrich; Achim Schmidtko; Irmgard Tegeder; Gerd Geisslinger
Journal:  Pain       Date:  2004-07       Impact factor: 6.961

8.  Expression and activity of cyclin-dependent kinase 5/p35 in adult rat peripheral nervous system.

Authors:  M Terada; H Yasuda; S Kogawa; K Maeda; M Haneda; H Hidaka; A Kashiwagi; R Kikkawa
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

9.  Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression.

Authors:  M R Hellmich; H C Pant; E Wada; J F Battey
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.

Authors:  Jonathan C Cruz; Huang-Chun Tseng; Joseph A Goldman; Heather Shih; Li-Huei Tsai
Journal:  Neuron       Date:  2003-10-30       Impact factor: 17.173

View more
  55 in total

1.  The Cdk5 kinase downregulates ATP-gated ionotropic P2X3 receptor function via serine phosphorylation.

Authors:  Asha Nair; Manuela Simonetti; Elsa Fabbretti; Andrea Nistri
Journal:  Cell Mol Neurobiol       Date:  2009-12-04       Impact factor: 5.046

2.  Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.

Authors:  David Askew; Tej K Pareek; Saada Eid; Sudipto Ganguly; Megan Tyler; Alex Y Huang; John J Letterio; Kenneth R Cooke
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

3.  Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.

Authors:  Justin V Louis; Ellen Martens; Peter Borghgraef; Caroline Lambrecht; Ward Sents; Sari Longin; Karen Zwaenepoel; Robert Pijnenborg; Isabelle Landrieu; Guy Lippens; Birgit Ledermann; Jürgen Götz; Fred Van Leuven; Jozef Goris; Veerle Janssens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  An Interstitial 17q11.2 de novo Deletion Involving the CDK5R1 Gene in a High-Functioning Autistic Patient.

Authors:  Carla Lintas; Roberto Sacco; Claudio Tabolacci; Claudia Brogna; Marco Canali; Chiara Picinelli; Pasquale Tomaiuolo; Paola Castronovo; Marco Baccarin; Antonio M Persico
Journal:  Mol Syndromol       Date:  2018-08-01

Review 5.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

6.  Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1.

Authors:  Tej K Pareek; Jason Keller; Sashi Kesavapany; Nitin Agarwal; Rohini Kuner; Harish C Pant; Michael J Iadarola; Roscoe O Brady; Ashok B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

7.  Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.

Authors:  Wei Wang; Xiaoning Cao; Xiaolei Zhu; Yongliang Gu
Journal:  J Mol Model       Date:  2013-03-23       Impact factor: 1.810

8.  Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.

Authors:  Tej K Pareek; Eric Lam; Xiaojing Zheng; David Askew; Ashok B Kulkarni; Mark R Chance; Alex Y Huang; Kenneth R Cooke; John J Letterio
Journal:  J Exp Med       Date:  2010-10-11       Impact factor: 14.307

9.  Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35.

Authors:  Elias Utreras; Akira Futatsugi; Parvathi Rudrabhatla; Jason Keller; Michael J Iadarola; Harish C Pant; Ashok B Kulkarni
Journal:  J Biol Chem       Date:  2008-12-02       Impact factor: 5.157

10.  Gene network and pathway analysis of bovine mammary tissue challenged with Streptococcus uberis reveals induction of cell proliferation and inhibition of PPARgamma signaling as potential mechanism for the negative relationships between immune response and lipid metabolism.

Authors:  Kasey M Moyes; James K Drackley; Dawn E Morin; Massimo Bionaz; Sandra L Rodriguez-Zas; Robin E Everts; Harris A Lewin; Juan J Loor
Journal:  BMC Genomics       Date:  2009-11-19       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.